# US 2021/0340620 A1 · Cell potency assay for therapeutic potential

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340620 A1
- Document ID: US20210340620A1
- Status: Published application
- Kind: A1
- Application number: 17/096,787
- Filed: 2020-11-12
- Published: 2021-11-04
- Earliest claimed: 2013-03-15
- Assignees: Fate Therapeutics, Inc.
- Applicants: Fate Therapeutics, Inc.
- Inventors: Daniel Shoemaker; David L. Robbins
- Web page: https://patentgrep.com/patent/US20210340620A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 35/00: Antineoplastic agents
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides cell potency assays for measuring, determining, identifying, confirming, or validating the therapeutic potential of a cell population. Cell potency assays may be performed with various types of cells, including stem or progenitor cells, such as, for example, hematopoietic stem or progenitor cells. Cell potency assays may also be performed on stem or progenitor cells that have been treated with one or more agents to enhance therapeutic potential. Hematopoietic cells having therapeutic potential are useful in downstream clinical applications for increasing engraftment, reconstitution, homing, and proliferation in vivo.

## Claims

### Claim at position 1

1-48. (canceled)

### Claim 49

An in vitro or ex vivo method to determine the therapeutic potential of a population of cells comprising:
a) measuring expression of a plurality of genes in a population of cells comprising hematopoietic cells;
b) identifying increased expression in at least two of the plurality of genes in the population of cells compared to a control population of cells;
wherein the hematopoietic cells have sufficient therapeutic potential if the increased expression in the at least two of the plurality of genes in the population of cells is at least two-fold.

### Claim 50 (depends on 49)

The method of claim 49, wherein the population of cells is bone marrow cells (BMCs), umbilical cord blood cells (UCBCs), placental blood cells, mobilized peripheral blood cells (MPBCs), hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), or CD34+ cells.

### Claim 51

(canceled)

### Claim 52 (depends on 49)

The method of claim 49, wherein at least a portion of the population of cells is modulated ex vivo prior to measuring expression of the plurality of genes.

### Claim 53 (depends on 49)

The method of claim 49, wherein at least a portion of the population of cells is expanded ex vivo prior to measuring expression of the plurality of genes.

### Claim 54 (depends on 49)

The method of claim 49, wherein at least a portion of the population of cells is cryopreserved prior to measuring expression of the plurality of genes.

### Claim at position 8

55-56. (canceled)

### Claim 57 (depends on 49)

The method of claim 49, wherein the population of cells is modulated ex vivo prior to measuring expression of the plurality of genes by contacting the population of cells with at least one agent selected from the group consisting of a cAMP analogue or enhancer, a Ga-s activator, and a prostaglandin pathway agonist.

### Claim 58 (depends on 57)

The method of claim 57, wherein the prostaglandin pathway agonist selectively binds the PGE2 EP2 or PGE2 EP4 receptor.

### Claim 59 (depends on 57)

The method of claim 57, wherein the prostaglandin pathway agonist comprises PGE2, or a PGE2 analogue or derivative.

### Claim 60 (depends on 57)

The method of claim 57, wherein the prostaglandin pathway agonist is selected from the group consisting of: PGE2, 16,16-dmPGE2, 15(S)-15-methyl PGE2, 20-ethyl PGE2, and 8-iso-16-cyclohexyl-tetranor PGE2.

### Claim 61 (depends on 57)

The method of claim 57, wherein the prostaglandin pathway agonist comprises 16,16-dmPGE2.

### Claim 62 (depends on 57)

The method of claim 57, wherein the population of cells is further contacted with a glucocorticoid.

### Claim at position 15

63-68. (canceled)

### Claim 69 (depends on 57)

The method of claim 57, wherein the population of cells has been contacted with the at least one agent for a time of at least about one hour to at least about 24 hours.

### Claim at position 17

70-73. (canceled)

### Claim 74 (depends on 57)

The method of claim 57, wherein the population of cells has been contacted with the at least one agent at a temperature of about 37° C.

### Claim at position 19

75-78. (canceled)

### Claim 79 (depends on 49)

The method of claim 49, wherein the plurality of genes comprises two or more genes selected from the group consisting of: hairy/enhancer-of-split related with YRPW motif 1 (HEYi), UL16 binding protein 2 (ULBP2), hyaluronan synthase 1 (HASI), GTP-binding protein GEM (GEM), renin (REN), collagen, type I, alpha 1 (COLIAI), cyclooxygenase 2 (COX-2), angiopoietin 1 (ANGPTI), chemokine (C-X-C motif) ligand 6 (CXCL6), prominin 1 (PROMI), bone morphogenetic protein 4 (BMP4), angiopoietin 2 (ANGPT2), inhibitor of kappaB kinase beta (IKBKB), platelet/endothelial cell adhesion molecule 1 (PECAMI), tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIEI), amphiregulin (AREG), caspase 3 (CASP3), jagged 1 (JAGI), aryl hydrocarbon receptor nuclear translocator (ARNT), cAMP-responsive element modulator (CREM), connective tissue growth factor (CTGF), CD40 ligand (CD40L), BCL2-associated X protein (BAX), hepatocyte growth factor (HGF), superoxide dismutase 2 (SOD2), platelet derived growth factor B (PDGFB), thrombospondin 1 (THBSI), dual specificity protein phosphatase 4 (DUSP4), cysteine-rich protein 61 (CYR61), chemokine (C-X-C motif) ligand 1 (CXCLI), endothelial tyrosine kinase (TEK), CASP8 and FADD-like apoptosis regulator (CFLAR), insulin growth factor 2 (IGF2), chemokine (C-X-C motif) receptor 4 (CXCR4), matrix metalloprotease 2 (MMP2), fibroblast growth factor 2 (FGF2), prostaglandin endoperoxide synthase 2 (PTGS2), RAS-related C3 botulinum substrate 2 (RAC2), platelet derived growth factor receptor (PDGFR), nuclear receptor subfamily 4, group A, member 2 (NR4A2), nuclear receptor subfamily 4, group A, member 3 (NR4A3), telomerase reverse transcriptase (TERT), transforming growth factor beta 1 (TGFBI), matrix metalloprotease 9 (MMP9), CD40 antigen (CD40), CD44 antigen (CD44), high mobility group box 1 (HMGBI), nitrogen oxide synthase 3 (NOS3), kinase insert domain receptor (KDR), integrin beta 1 (ITGBI), catenin (cadherin-associated protein), beta 1 (CTNNBI), colony stimulating factor 3 (CSF3), interleukin 8 (IL8), plasminogen activator, urokinase receptor (PLAUR), B cell CLL/lymphoma 2 (BCL2), bone morphogenetic protein 2 (BMP2), colony stimulating factor 1 (CSFI), v-akt murine thymoma viral oncogene homolog 1 (AKTI), vascular endothelial growth factor A (VEGFA), intercellular adhesion molecule 1 (ICAMI), chemokine (C-X-C motif) ligand 3 (CXCL3), caspase 8 (CASP8), CD34 antigen (CD34), interleukin IA (IL1A), CD47 antigen (CD47), chemokine (C-C motif) ligand 7 (CCL7), hypoxia inducible factor IA (HIFIA), EDNI (endothelin 1), sphingosine-1-phosphate receptor 1 (SIPRI), chemokine (C-C motif) receptor 1 (CCRI), SMAD family member 4 (SMAD4), fms-related tyrosine kinase 1 (FLTI), CD151 antigen (CD151), placental growth factor (PGF), nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB 1), SMAD family member 2 (SMAD2), CXC chemokine receptor 7 (CXCR7), transforming growth factor beta 3 (TGFB3), chemokine (C-X-C motif) ligand 5 (CXCL5), cyclin DI (CCNDI), heparin-binding EGF-like growth factor (HBEGF), nuclear receptor subfamily 3, group C, member 1 (NR3C1), tumor necrosis factor (TNF), integrin alpha L (ITGAL), CXC chemokine receptor 2 (CXCR2), signal transducer and activator of transcription 1 (STATI), integrin alpha 4 (ITGA4), leukemia inhibitory factor (LIF), RAS p21 protein activator 1 (RASAI), cadherin 5 (CDH5), ephrin B2 (EFNB2), regulator of G-protein signaling 16 (RGS16), chemokine (C-X-C motif) ligand 2 (CXCL2), integrin alpha 5 (ITGA5), chemokine (C-X-C motif) ligand 12 (CXCL12), tissue inhibitor of metalloprotease 1 (TEMPI), Fos related antigen 2 (FOSL2), integrin beta 2 (ITGB2), and tissue inhibitor of metalloprotease 2 (TIMP2).

### Claim at position 21

80-105. (canceled)

### Claim 106 (depends on 49)

A method of increasing hematopoietic engraftment in a subject, comprising administering a population of hematopoietic cells having sufficient therapeutic potential according to claim 49 to increase hematopoietic engraftment in the subject.

### Claim 107

(canceled)

### Claim 108 (depends on 106)

The method of claim 106, wherein the hematopoietic engraftment is increased about 10% by hematopoeitic cells that have therapeutic potential compared to the engraftment associated with control hematopoietic cells.

### Claim at position 25

109-112. (canceled)

### Claim 113 (depends on 106)

The method of claim 106, wherein the hematopoietic engraftment is increased about two-fold by hematopoeitic cells that have therapeutic potential compared to the engraftment associated with control hematopoietic cells.

### Claim at position 27

114-115. (canceled)

### Claim 116 (depends on 49)

A method of cell-based therapy, comprising administering a population of autologous hematopoietic cells having sufficient therapeutic potential according to claim 49 to a subject in need thereof.

### Claim 117 (depends on 49)

A composition comprising a population of hematopoietic cells having therapeutic potential according claim 49.

### Claim 118

A gene expression panel for identifying a population of hematopoietic cells having therapeutic potential, comprising a plurality of genes selected from the group consisting of: HEYi, COX2, ULBP2, HASI, GEMi, REN, COLIAI, ANGPTI, CXCL6, PROMI, BMP4, ANGPT2, IKBKB, PECAMI, TIEI, AREG, CASP3, JAGI, ARNT, CREM, CTGF, CD40L, BAX, HGF, SOD2, PDGFB, THBSI, DUSP4, CYR61, CXCLI, TEK, CFLAR, IGF2, CXCR4, MMP2, FGF2, PTGS2, RAC2, PDGFR, NR4A2, NR4A3, TERT, TGFBI, MMP9, CD40, CD44, HMGBI, NOS3, KDR, ITGBI, CTNNBI, CSF3, IL8, PLAUR, BCL2, BMP2, CSFI, AKTI, VEGFA, ICAMI, CXCL3, CASP8, CD34, IL1A, CD47, CCL7, HIFIA, EDNI, SIPRI, CCRI, SMAD4, FLTI, CD151, PGF, NFKBI, SMAD2, CXCR7, TGFB3, CXCL5, CCNDI, HBEGF, NR3C1, TNF, ITGAL, CXCR2, STATI, ITGA4, LIF, RASAI, CDH5, EFNB2, RGS16, CXCL2, ITGA5, CXCL12, TIMPI, FOSL2, ITGB2, and TIMP2.

### Claim at position 31

119-123. (canceled)
